Researchers have found a surprisingly common vulnerability in a broad variety of cancers and have begun designing drug compounds to exploit it, in a study led by investigators at Weill Cornell ...

Depression continues to grapple a large proportion of the population. Given the side effects associated with the long-term use of conventional antidepressants, there is a need for novel rapid acting ...

Bowel side effects were very low, with no patients in the two-session group reporting bowel side effects. "After two years, our patients reported minimal change in their quality of life. There was no ...

Please provide your email address to receive an email when new articles are posted on . INDIANAPOLIS — In this Healio video, Kaleb Abbott, OD, MS, FAAO, assistant professor at University of Colorado ...

This segment highlights a real-world patient perspective on immunotherapy tolerability in advanced melanoma. Ms. Haupert shares that she experienced minimal side effects during treatment, primarily ...

ROCHESTER, Minn. -- Mayo Clinic investigators have found that the medication mycophenolate mofetil is effective for managing symptoms of systemic lupus erythematosus (SLE), the most common type of ...

Drugs targeting the protein Wee1 looked promising, but an incomplete understanding of their mechanism likely led to the ...

Zealand Pharma A/S said moderate doses of its experimental weight-loss drug helped patients pare pounds with less nausea than some other next-generation contenders in the growing market for obesity ...

AstraZeneca said its experimental weight loss pill was well tolerated by patients in an early-stage clinical trial. The Anglo-Swedish drugmaker’s closely watched weight loss pill, AZD5004, showed 5.8% ...

The global burden of anxiety- and depression-related disorders is on the rise. While multiple drugs have been developed to treat these conditions, current medications have several limitations, ...

Photo of a glass etched, cryo-electron microscopy-based representation of the TNKS2 enzymatic domain bound to TDI-012804, the TNKS2-selective inhibitor described in this study.